Vcanbio Cell & Gene Engineering Corp., Ltd.SSE: 600645

Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection

· Issued by Vcanbio Cell & Gene Engineering Corp., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 3 pages · Chinese

Summary by 6ix AI

The clinical trial has officially started with the first subject receiving treatment, marking the initiation of Phase Ib/II trials. The announcement includes details about the drug's specifications and its registration as a therapeutic biological product. The company emphasizes the need for clinical trials and regulatory approval before the drug can be marketed.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Vcanbio Cell & Gene Engineering Corp., Ltd. on 6ix

Earlier from Vcanbio Cell & Gene Engineering

Later from Vcanbio Cell & Gene Engineering

All Vcanbio Cell & Gene Engineering news releases